Study comes amid growing concerns about the over-reliance on Nexium, Prilosec and other PPI drugs, and after the drug makers paid millions to settle lawsuits over failure to warn about the kidney damage risks.
Drug maker agreed to settle all Nexium, Prilosec lawsuits brought by former users diagnosed with kidney failure, kidney disease or other kidney injuries.
Researchers found that serious childhood infection risks were even higher for those children who had taken PPIs both before, and during, the study.
The findings come as manufacturers of Nexium, Prilosec and similar heartburn drugs face a growing number of lawsuits over kidney damage
A series of three bellwether trials involving kidney damage lawsuits over Nexium, Prilosec and other heartburn drugs will go before juries in October 2023, November 2023 and January 2024
Taking heartburn medications like Nexium and Prilosec at the same time as Ibrance or other breast cancer drugs was linked to a 15-month shorter survival rate for women with advanced diagnosis
Two additional bellwether trials are scheduled to begin in July and September 2023, which will help gauge how juries may respond to evidence about the risk of kidney damage from Nexium, Prilosec and other PPIs
Use of Nexium, Prilosec and similar heartburn drugs was linked to a nearly 50% increased risk of developing a drug-treatment resistant infection, researchers found.
Bellwether jury trial for the first Nexium kidney damage lawsuit was originally scheduled to begin on November 14, 2022. However, the start has been postponed as parties meet to discuss settlement
A series of settlement conferences will be held with drug makers in September and October 2022, weeks before the first Nexium lawsuit is set to go before a jury involving kidney disease caused by the heartburn drug
